Δ9-Tetrahydrocannabivarin (oral gummy)

Phase 2

Δ9-Tetrahydrocannabivarin (oral gummy) is one of 6 therapeutic programs targeting Tobacco Use Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Tobacco Use DisorderNot yet recruiting

Tobacco Use DisorderPhase 2

Not yet recruiting

Competition

Competitive Landscape

6 competitors in Tobacco Use Disorder

#DrugCompanyPhaseTrials

Chantix

PPrism Pharmaceuticals

Phase 2

2 2

Chantix

Pfizer

Phase 1

1 3

Wellbutrin

GGlaxo Dba Glaxosmithkline

Preclinical

1 4

Δ9-Tetrahydrocannabivarin (oral gummy)

UUniversity of California, Los Angeles

Phase 2

1 5

Nicotine Replacement Therapies

NNYU Langone Health

Preclinical

1 6

Nicotine Replacement Therapy

VVA Office of Research and Development

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Not yet recruiting

Tobacco Use Disorder

NCT07636356

Clinical

Trials by Indication[1]

Tobacco Use Disorder1 trial

Development of Tetrahydrocannabivarin as a Treatment for Smokers

Not yet recruiting·UUniversity of California, Los Angeles·Phase 2·NCT07636356·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Δ9-Tetrahydrocannabivarin (oral gummy). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Δ9-Tetrahydrocannabivarin (oral gummy). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of California, Los Angeles company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: UUniversity of California, Los Angeles

Δ9-Tetrahydrocannabivarin (oral gummy)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Tobacco Use Disorder1 trial

References

Drug Info

Quick Facts

Related News